Gurses Nurcan, Topcul Mehmet
Department of Biology, Institute of Science, Istanbul University, Istanbul, Turkey.
Asian Pac J Cancer Prev. 2013;14(7):4229-33. doi: 10.7314/apjcp.2013.14.7.4229.
Abraxane (nab-paclitaxel) is a member of the group of nano chemotherapeutics. It is approved for metastatic breast cancer and non small cell lung cancer. Trials for several cancer types including gynecological cancers, head and neck, and prostatic cancer are being studied. In this study, the antiproliferative and apoptotic effect of abraxane was evaluated on HeLa cell line originated from human cervix carcinoma. Three different doses (D1=10 nM, D2=50 nM, D3=100 nM) were administered to HeLa cells for 24, 48 and 72 h. The 50 nM dose of abraxane decreased DNA synthesis from 4.62-0.08%, mitosis from 3.36-1.89% and increased apoptosis from 10.6-30% at 72 h. Additionally, tripolar metaphase plates were seen in mitosis preparations. In this study, abraxane effected cell kinetic parameters significantly. This results are consistent with other studies in the literature.
艾日布林(纳米紫杉醇)是纳米化疗药物组的一员。它被批准用于治疗转移性乳腺癌和非小细胞肺癌。目前正在对包括妇科癌症、头颈癌和前列腺癌在内的几种癌症类型进行试验。在本研究中,评估了艾日布林对源自人宫颈癌的HeLa细胞系的抗增殖和凋亡作用。向HeLa细胞施加三种不同剂量(D1 = 10 nM,D2 = 50 nM,D3 = 100 nM),处理24、48和72小时。在72小时时,50 nM剂量的艾日布林使DNA合成从4.62%降至0.08%,有丝分裂从3.36%降至1.89%,并使凋亡从10.6%增加至30%。此外,在有丝分裂制片中观察到三极中期板。在本研究中,艾日布林显著影响细胞动力学参数。这些结果与文献中的其他研究一致。